U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07231250) titled 'Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma' on Nov. 13.
Brief Summary: This is a multi-center, phase II, prospective study. The main purpose of study is to evaluate the efficacy and safety of Glofitamab plus Polatuzumab vedotin and Zuberitamab in patients with newly diagnosed diffuse large B-cell lymphoma.
Study Start Date: Jan. 15, 2026
Study Type: INTERVENTIONAL
Condition:
DLBCL - Diffuse Large B Cell Lymphoma
Chemo-free Therapy
Bispecific Antibody
Intervention:
DRUG: Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone...